Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis

被引:55
|
作者
Asefi, M. [1 ]
Vaisi-Raygani, A. [1 ,2 ,3 ]
Bahrehmand, F. [1 ]
Kiani, A. [6 ]
Rahimi, Z. [1 ,4 ]
Nomani, H. [1 ]
Ebrahimi, A. [5 ]
Tavilani, H. [7 ]
Pourmotabbed, T. [8 ]
机构
[1] Kermanshah Univ Med Sci, Mol Diagnost Res Ctr, Kermanshah, Iran
[2] Kermanshah Univ Med Sci, Dept Clin Biochem, Kermanshah, Iran
[3] Kermanshah Univ Med Sci, Fertil & Infertil Res Ctr, Kermanshah, Iran
[4] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran
[5] Kermanshah Univ Med Sci, Dept Dermatol, Kermanshah, Iran
[6] Shahid Behashti Univ Med Sci, Sch Pharm, Dept Pharmacol & Toxicol, Tehran, Iran
[7] Hamadan Univ Med Sci, Dept Clin Biochem, Hamadan, Iran
[8] Univ Tennessee, Hlth Sci Ctr, Dept Microbiol Immunol & Biochem, Knoxville, TN 37996 USA
关键词
HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; GENE POLYMORPHISM; APOLIPOPROTEIN LEVELS; BIOLOGICAL-ACTIVITY; INCREASED RISK; SERUM; PATHOGENESIS; ENZYME;
D O I
10.1111/j.1365-2133.2012.11170.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Paraoxonase 1 (PON1) is a serum high-density lipoprotein-bound enzyme with antioxidant function. It hydrolyses lipid peroxides, protecting low-density lipoproteins from oxidative modifications. Patients with psoriasis are at greater risk of oxidative stress, which is associated with abnormal plasma lipid metabolism. Objectives In this study, association of the PON1 55 M allele with serum arylesterase (ARE) activity, malondialdehyde (MDA), lipid profiles and psoriasis was investigated. Methods The present casecontrol study consisted of 100 patients with psoriasis with and without cardiovascular diseases (mean age 35.3 years) and 100 sex- and age-matched unrelated healthy controls (mean age 35.7 years) from the population of western Iran. The PON1 55 Met>Leu polymorphism was detected by polymerase chain reactionrestriction fragment length polymorphism. Serum ARE activity, MDA, and lipid and apolipoprotein levels were determined spectrophotometrically, by high-performance liquid chromatography and by enzyme assay, respectively. Results The presence of the PON1 55 M allele was found to be associated with psoriasis (odds ratio = 1.96, P = 0.017). The patients with psoriasis with the PON1 M (M/L + M/M) allele had higher MDA levels (4.12 +/- 0.88 vs. 2.24 +/- 0.55 mu mol L-1, P < 0.001), apolipoprotein B (APOB)/APOA1 ratio (0.91 +/- 0.66 vs. 0.66 +/- 0.35, P = 0.004), APOB (111 +/- 38.7 vs. 88.3 +/- 22.5 mg mL(-1), P = 0.001) and lipoprotein(a) [LP(a)] (21.9 +/- 18.4 vs. 15.8 +/- 16.6 mg mL(-1), P = 0.034), but lower ARE activity (39.6 +/- 11 vs. 45.9 +/- 11.8 U mL(-1), P = 0.031) than the control subjects. ARE activity showed a significant positive correlation with APOA1 and a negative correlation with MDA concentration in patients with psoriasis. Conclusions The PON1 55 M allele is a risk factor for psoriasis. Carriers of this allele have high levels of MDA, APOB and LP(a), a high APOB/APOA1 ratio and low ARE activity. These results indicate that oxidative stress, impairment of the antioxidant system and abnormal lipid metabolism may play a role in the pathogenesis and progression of psoriasis and its related complications. These data suggest that patients with psoriasis are more susceptible to vascular diseases.
引用
收藏
页码:1279 / 1286
页数:8
相关论文
共 50 条
  • [1] Paraoxonase 1 (PON1) L55M and Q192R polymorphisms, lipid profiles and psoriasis
    Hernandez Collazo, A. Abraham
    Alvarado Navarro, A.
    Fafutis Morris, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2017, 137 (05) : S82 - S82
  • [2] Paraoxonase (PON1) 55 Polymorphism and Association with Systemic Lupus Erythematosus
    Bahrehmand, Fariborz
    Vaisi-Raygani, Asad
    Ahmadi, Reza
    Kiani, Amir
    Rahimi, Zohreh
    Tavilani, Haidar
    Pourmotabbed, Tayebeh
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2013, 12 (03) : 211 - 219
  • [3] GENETIC POLYMORPHISM IN PARAOXONASE 1 (PON1): POPULATION DISTRIBUTION OF PON1 ACTIVITY
    Ginsberg, Gary
    Neafsey, Patricia
    Hattis, Dale
    Guyton, Kathryn Z.
    Johns, Douglas O.
    Sonawane, Babasaheb
    JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2009, 12 (5-6): : 473 - 507
  • [4] Association of paraoxonase 1 (PON1) L55M and PON1 Q192R gene polymorphisms and risk of psoriasis
    Kalkan, Goknur
    Seckin, Havva Y.
    Benli, Ismail
    Akbas, Ali
    Ates, Omer
    Ozyurt, Huseyin
    Bas, Yalcin
    Ogrum, Atiye
    Pancar, Gunseli S.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2019, 154 (03): : 321 - 326
  • [5] A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
    Suehiro, T
    Nakamura, T
    Inoue, M
    Shiinoki, T
    Ikeda, Y
    Kumon, Y
    Shindo, M
    Tanaka, H
    Hashimoto, K
    ATHEROSCLEROSIS, 2000, 150 (02) : 295 - 298
  • [6] Association between paraoxonase 1 (PON1) enzyme activity, PON1 C(−107)T polymorphism, nutritional status, and lipid profile in children
    Uliano G.
    Muniz L.C.
    Barros C.C.
    Schneider A.
    Valle S.C.
    Nutrire, 41 (1)
  • [7] Paraoxonase 1 (PON1) activity and lipid parameters in Tunisian smokers
    不详
    ANNALES DE BIOLOGIE CLINIQUE, 2010, 68 (02) : 143 - 147
  • [8] Discordance in the paraoxonase (PON1)-192QR polymorphism
    Poh, Rozaida
    Muniandy, Sekaran
    BIOMEDICAL RESEARCH-INDIA, 2008, 19 (01): : 33 - 36
  • [9] THE HUMAN PARAOXONASE-1 (PON1) PHENOTYPE MODIFIES THE EFFECT OF STATINS ON PON1 ACTIVITY AND LIPID PARAMETERS
    Paragh, G.
    Mirdamadi, H.
    Harangi, M.
    Sztanek, F.
    Derdak, Z.
    Kassai, A.
    Seres, I.
    ATHEROSCLEROSIS SUPPLEMENTS, 2009, 10 (02)
  • [10] Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson's disease
    Kondo, I
    Yamamoto, M
    BRAIN RESEARCH, 1998, 806 (02) : 271 - 273